Abstract:Inorganic arsenic (iAs) is an environmental toxicant associated with an increased risk of prostate cancer in chronically exposed populations worldwide. However, the biological mechanisms underlying iAs-induced prostate carcinogenesis remain unclear. We studied how iAs affects normal human prostate stem-progenitor cells (PrSPCs) and drives transformation and interrogated the molecular mechanisms involved. PrSPCs were enriched by spheroid culture from normal human primary or immortalized prostate epithelial cells, and their differentiation capability was evaluated by organoid culture. Microarray analysis was conducted to identify iAs-dysregulated genes, and lentiviral infection was used for stable manipulation of identified genes. Soft agar colony growth assays were applied to examine iAs-induced transformation. For study, PrSPCs mixed with rat urogenital sinus mesenchyme were grafted under the renal capsule of nude mice to generate prostatelike tissues, and mice were exposed to () iAs in drinking water for 3 months. Low-dose iAs () disturbed PrSPC homeostasis , leading to increased self-renewal and suppressed differentiation. Transcriptomic analysis indicated that iAs activated oncogenic pathways in PrSPCs, including the KEAP1-NRF2 pathway. Further, iAs-exposed proliferative progenitor cells exhibited NRF2 pathway activation that was sustained in their progeny cells. Knockdown of NRF2 inhibited spheroid formation by driving PrSPC differentiation, whereas its activation enhanced spheroid growth. Importantly, iAs-induced transformation was suppressed by knockdown. Mechanistically, iAs suppressed Vacuolar ATPase subunit VMA5 expression, impairing lysosome acidification and inhibiting autophagic protein degradation including p62, which further activated NRF2. , chronic iAs exposure activated NRF2 in both epithelial and stroma cells of chimeric human prostate grafts and induced premalignant events. Low-dose iAs increased self-renewal and decreased differentiation of human PrSPCs by activating the p62-NRF2 axis, resulting in epithelial cell transformation. NRF2 is activated by iAs through specific autophagic flux blockade in progenitor cells, which may have potential therapeutic implications. https://doi.org/10.1289/EHP6471.

What problem does this paper attempt to address?

This paper aims to explore the effects of inorganic arsenic (iAs) on human prostate stem/progenitor cells (PrSPCs), especially how it causes cell transformation, autophagy flux blockade and NRF2 pathway activation. Specifically, the researchers focused on whether low - dose inorganic arsenic can interfere with the homeostasis of PrSPCs, increase self - renewal ability while inhibiting differentiation, and explored the molecular mechanisms behind these changes. In addition, the study also evaluated the possibility that iAs activates the NRF2 pathway in progenitor cells through specific autophagy flux blockade, which may have potential significance for treatment. ### Research Background Inorganic arsenic is a widely distributed environmental and industrial toxicant and is classified as a Group 1 carcinogen by the International Agency for Research on Cancer (IARC). More than 137 million people live in arsenic - exposed environments that exceed the drinking water standard (10 ppb, or 0.13 μM) set by the United States Environmental Protection Agency (EPA). Epidemiological studies have shown that chronic arsenic exposure is associated with an increased risk of certain cancers, especially the incidence and mortality of prostate cancer. However, the specific biological mechanisms by which iAs induces prostate carcinogenesis are still unclear. ### Research Objectives The main objectives of this study are: 1. **Explore the effects of iAs on normal human prostate stem/progenitor cells (PrSPCs)**: Study how iAs affects the self - renewal and differentiation abilities of PrSPCs. 2. **Analyze the mechanism of iAs - induced cell transformation**: Through transcriptome analysis and functional experiments, explore how iAs activates oncogenic pathways, especially the KEAP1 - NRF2 pathway. 3. **Evaluate the effects of iAs on autophagy flux**: Study how iAs activates the NRF2 pathway by inhibiting autophagy flux, and then affects the homeostasis of PrSPCs. ### Methods - **Cell culture and treatment**: PrSPCs were enriched from primary prostate epithelial cells (PrECs) of young organ donors and cultured in 3D spheroids (prostasphere, PS) and organoids. - **Transcriptome analysis**: Microarray technology was used to analyze the gene expression changes in PrSPCs before and after iAs treatment. - **Functional experiments**: Including soft agar colony - formation assay, Hoechst exclusion assay, immunoblotting and immunofluorescence staining, etc. - **In vivo experiments**: PrSPCs were mixed with rat urogenital sinus mesenchyme (UGM) and then transplanted under the renal capsule of nude mice to evaluate the effects of long - term iAs exposure on the transplanted tissues. ### Results - **Low - dose iAs (1 μM) increased the self - renewal ability of PrSPCs and decreased differentiation**, while high - dose iAs (5 - 50 μM) had the opposite effect. - **Transcriptome analysis showed** that iAs activated oncogenic pathways in PrSPCs, especially the KEAP1 - NRF2 pathway. - **iAs activates the NRF2 pathway by inhibiting the expression of V - ATPase subunit VMA5**, which hinders lysosomal acidification and inhibits autophagic protein degradation. - **The results of in vivo experiments showed** that long - term iAs exposure activated NRF2 in the epithelial and stromal cells of chimeric human prostate grafts and induced precancerous lesions. ### Conclusions Low - dose iAs increases the self - renewal ability of human PrSPCs and decreases differentiation by activating the p62 - NRF2 axis, leading to epithelial cell transformation. The activation of NRF2 is achieved in progenitor cells through specific autophagy flux blockade, and this finding may have potential significance for treatment.

Effects of Inorganic Arsenic on Human Prostate Stem-Progenitor Cell Transformation, Autophagic Flux Blockade, and NRF2 Pathway Activation.